Search

Great things in business are never done by one person; they’re done by a team of people

Generalized pustular psoriasis: Unmet needs

Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the impact of living with GPP including unseen challenges and future management.

Generalized pustular psoriasis: Value of community support

Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the importance of knowledge sharing, community support and challenges faced by those living with GPP.

Embracing diversity in clinical trials

At Boehringer Ingelheim, we understand the crucial need of embracing diversity in clinical trials as an opportunity to enable more equitable healthcare.

Rethinking mental health care

Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals

Breakthrough Phase 2 survodutide data liver fibrosis MASH

Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

Phase 1 start for novel triple agonist obesity treatment

Boehringer and Gubra announce Phase 1 study of BI 3034701, a long-acting, next generation, first-in-class triple agonist peptide for obesity treatment

Boehringer Ingelheim advances SIRP immune-oncology program

Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371

Boehringer Ingelheim strong growth pipeline acceleration 2023

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

Vaccine bluetongue virus serotype 3 sheep cattle

BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.

Dedifferentiated liposarcoma (DDLPS)

An aggressive subtype of a category of cancers called soft tissue sarcoma (STS). DDLPS has a poor prognosis and limited treatment options.

Do we keep our promise?

Find out from a father-daughter duo how we live up to our new People Promise.

Results for Jardiance EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack

Fabio Paganini fostering inclusion & agility in AH

How employees are contributing to an inclusive culture at Boehringer Ingelheim.

Boehringer Olaf Scholz break ground for innovation center

Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center

New partnership to develop schizophrenia treatments

Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments

Boehringer Ingelheim half-year results 2023

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Data Science

Revolutionizing research and development with data driven insights

EU approved Jardiance for type 2 diabetes in children

Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above